Business Strategies

Public Company Edition: Biomedtracker data show the amount of money raised in both PIPEs and follow-on offerings surging in 2024. Olema and Cidara raised $250m and $105m, respectively, in recent private placements, while Spyre and Replimune grossed $200m and $140m in FOPOs.

After completing due diligence, private equity firm Brookfield is reportedly close to launching an offer of €10.50 euros per share to acquire the Spanish major. Given that at least one investor believes Grifols is worth at least €20 a share, sparks could fly.

The US firm wants to hook up with the German group to create a global innovative services company but its €11.00 per share cash offer looks unlikely to sway Evotec shareholders.

23andMe cut 40% of its workforce and will discontinue its therapeutic program as part of ongoing restructuring. This comes after a data breach, series of layoffs and the resignation of its board members.

France’s medtech sector is strong, growing and innovative. Medtech Insight spoke to several French medtech leaders about the unique features and pitfalls their industry may face.

Darrin Schellin leads Pharma Tech; PLT expands leadership with Weiss as brand mmanagement head; Tuttle joins ProPharma as CFO; Burgher leads Arbonne marketing, growth; Evvy appoints first medical chief; Vitaquest appoints David Alcaraz quality assurance head; and Lemon Water leadership in transition from founder.

23andMe cut 40% of its workforce and will discontinue its therapeutic program as part of ongoing restructuring. This comes after a data breach, series of layoffs and the resignation of its board members.

The Spanish company's Lilly-partnered atopic dermatitis drug is enjoying a decent launch in Germany and in other European countries, "we are getting the price that we wanted," claims CEO Carlos Gallardo.

Ex-Janssen India chief and BSV CEO Sanjiv Navangul shares with Scrip glimpses of his life and professional journey including chasing the IAS dream early on, the heady days at Hoechst with a stint in Moscow, challenges around Sirturo’s debut and unprecedented preps that fueled Januvia’s big run during his innings at MSD.

“The infant formula business is recovering and we've taken actions to simplify and consumerize our business, but there's a lot more work to do,” says CEO Patrick Lockwood-Taylor as Perrigo’s announced latest results.